Salute e Benessere

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's…

"We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to provide innovative and competitive ADC solutions," said Pei-Jiun Chen, CEO and President of Mycenax. "This collaboration further enhances our technical capabilities and reinforces our commitment to advancing next-generation ADC therapeutics." "We are thrilled to finalize this agreement with RIN Institute, marking an important milestone in our mission to…
PR Newswire
31/10/2025

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare…

$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial foundation toward self-sustainability and the advancement of next wave nanotherapeutic platforms for long-term growthHealthCare Royalty (HCRx) will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its global...
Nasdaq GlobeNewswire
31/10/2025

Correction: Bioretec Ltd's Half-year report 2025

The adjustment and restatement is related to the sales and distribution agreement with Tri-State Biologics ("TSB"), originally announced on 22 November 2024 (the "TSB Distribution Agreement"). The TSB Distribution Agreement was, upon its signing, based on a stocking distribution model, whereby TSB first purchases products from Bioretec for further sale and distribution by TSB to hospitals in the target geography. Following the signing of the TSB Distribution Agreement, a…
PR Newswire
31/10/2025

Vistin Pharma ASA: Third quarter and YTD 2025 financial results

Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31 stof October 2025Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025.Revenue in the third quarter ended at MNOK 109 compared to MNOK 106 in Q3 2024. The increase in revenue was driven by 10% higher sales volume. Revenue YTD 2025 ended at MNOK 342 compared to MNOK 316 YTD last year, an increase of 8%Third quarter EBITDA ended at MNOK 28 compared to MNOK 29 in Q3...
Nasdaq GlobeNewswire
31/10/2025

Luxury (High End) Lighting Market to Reach USD 35,220.96 million by 2032…

Browse the report and understand how it can benefit your business strategy - https://www.credenceresearch.com/report/luxury-lighting-market Browse the report and understand how it can benefit your business strategy -https://www.credenceresearch.com/report/luxury-lighting-market Market Overview The Luxury Lighting Market encompasses high-end fixtures designed not only for illumination but also as premium decorative and architectural elements. These products are characterized by...
PR Newswire
31/10/2025

Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During…

Atypical Teratoid/Rhabdoid Tumor Market Summary Atypical Teratoid/Rhabdoid Tumor Market Summary Discover the atypical teratoid/rhabdoid tumor new treatment @New Treatments for Atypical Teratoid/Rhabdoid Tumor Key Factors Driving the Growth of the Atypical Teratoid/Rhabdoid Tumor Market Deeper Molecular Understanding and Biomarker-Driven Biology Atypical teratoid/rhabdoid tumor is now understood as a genetically defined disease (most cases driven by bi-allelic loss of...
PR Newswire
30/10/2025

Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025

NyxoahtoReleaseThird Quarter 2025 Financial Results on November 13, 2025Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (EuronextBrussels/Nasdaq:NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the second quarter of 2025 on Thursday, November 13, 2025. Company management...
Nasdaq GlobeNewswire
30/10/2025

BIOVAXYS ANNOUNCES UPSIZING OF LIFE OFFERING OF UP TO $2M

Each Unit will consist of one common share of the Company (each, a "Share") and one common share purchase warrant (each, a "Warrant"), whereby each Warrant will entitle the holder thereof to acquire one additional Share at an exercise price of $0.40 for a period of 24 months from the date of issuance. Each Unit will consist of one common share of the Company (each, a " Share ") and one common share purchase warrant (each, a " Warrant "), whereby each…
PR Newswire
30/10/2025

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of…

DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV”), a clinical-stage biopharmaceutical company, today announced the provisional appointment of a new independent director, Dr. Philina Lee, to its Board of Directors (the “Board”), effective October 30, 2025. Dr. Lee is appointed in replacement of Daniel Soland, subject to the ratification by the Company’s...
Nasdaq GlobeNewswire
30/10/2025

Galapagos Announces Changes to its Board to Accelerate Strategic Focus on…

New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025, 21:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced several changes to its Board of Directors as part of its ongoing commitment to long-term governance and strategic continuity. These changes strengthen the alignment of the Board’s composition with the Company’s strategic direction and support its focus on...
Nasdaq GlobeNewswire
30/10/2025

TME Pharma publishes its semi annual results and half-year report

TME Pharma publishes its semi annual results and half-year reportBerlin, Germany , October 30, 2025, 21.00am CET–TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, publishes today its semi annual results and half-year report.The first half of the year was marked by TME Pharma's reorganization to a lower-cost outsourced staffing model. The results of this can be seen...
Nasdaq GlobeNewswire
30/10/2025

GENFIT announces intention to voluntarily delist American Depositary Shares from…

GENFIT’s decision to delist from Nasdaq reflects strategic intent to simplify corporate structure and improve operational efficiencyGENFIT remains listed on the regulated market of Euronext Paris as its primary trading marketLille (France), Cambridge (Massachusetts, United States), (Zurich, Switzerland); October 30, 2025 – GENFIT (Nasdaq and Euronext: GNFT),a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases,...
Nasdaq GlobeNewswire
30/10/2025

Thyroid Function Test Market to Reach USD 7,289.26 million by 2032, Growing At…

Market Overview Market Overview The Thyroid Function Test Market encompasses the full range of in-vitro diagnostic (IVD) assays used to assess the performance of the thyroid gland. This gland, located in the neck, produces hormones that regulate the body's metabolism, and its dysfunction can lead to a wide array of health problems. The primary tests in this market measure the levels of key hormones in the blood, including Thyroid-Stimulating Hormone (TSH), Thyroxine (T4), and...
PR Newswire
30/10/2025

Casino Group expands its Renouveau plan to 2030 and launches work to adapt its…

Casino Group expands its Renouveau plan to 2030 andlaunches work to adapt its financial structure Operating and financial results in line with the targets of the Renouveau 2028 plan Following a year of in-depth transformation in 2024,the first half of 2025 has marked a turning point : for the first time since its restructuring, Casino Group's like-for-like sales and margins are back on the rise:A return to growth for like-for-like net sales: up +2.4% in Q2 and +0.5% in H1;...
Nasdaq GlobeNewswire
30/10/2025

Casino Group: Third quarter 2025

THIRD-QUARTER 2025 Continuation of the first half-year's growth dynamic Growth in net sales: +0.5% LFL in Q3 and +0.6% over the first nine months The initial results of the “Renouveau” plan are confirmed, and the Group is again reporting like-for-like net sales growth this quarter.Roll out of the newstore concepts 25 Franprix stores remodelled with the"Oxygène"concept in Q3 (75 to date)3 additional Naturalia stores converted to the"La Ferme"concept in Q3 (23 to...
Nasdaq GlobeNewswire
30/10/2025

Cardiovascular, Renal & Metabolic (CRM) Diseases Market to Reach USD 451.87…

The upward trajectory in the CRM market is underpinned by several measurable factors: The upward trajectory in the CRM market is underpinned by several measurable factors: Download PDF Brochure:https://www.datamintelligence.com/download-sample/cardiovascular-renal-metabolic-diseases-market Browse in-depth TOC on 'Cardiovascular, Renal & Metabolic Diseases Market' 70 – Tables 66 – Figures 195 – Pages Market Segmentation: Detailing Key Growth Vectors By Disease...
PR Newswire
30/10/2025

Global Condom Market to Grow at 8.9% During 2026-32, Driven by Rising Awareness…

Download a FREE PDF Sample of the Report: https://www.marknteladvisors.com/query/request-sample/condom-market.html (Discover the market potential, platform-specific insights, and key industry trends.) Download a FREE PDF Sample of the Report: https://www.marknteladvisors.com/query/request-sample/condom-market.html(Discover the market potential, platform-specific insights, and key industry trends.) Global Condom Market size was valued at around USD 14.2 billionin 2025and is...
PR Newswire
30/10/2025

Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the…

Request Sample of the Report on Cystic Fibrosis (CF) Therapeutics Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/5499 Request Sample of the Report on Cystic Fibrosis (CF) Therapeutics Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/5499 Market Introduction The cystic fibrosis (CF) therapeutics market focuses on the development and commercialization of treatments designed to manage and alleviate the symptoms of CF, a genetic...
PR Newswire
30/10/2025

Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase…

Browse in-depth TOC on 'Competitive Landscape of Obesity Therapeutics Market' Browse in-depth TOC on 'Competitive Landscape of Obesity Therapeutics Market' 70 – Tables 66 – Figures 195 – Pages Competitive Landscape According to DataM Intelligence, key players in the obesity therapeutics market include:AstraZeneca,Rhythm Pharmaceuticals, Inc.,Takeda Pharmaceutical Company Limited, andKVK Tech, Inc.These firms are operating alongside dominant GLP-1 companies and...
PR Newswire
30/10/2025

Veterinary Biologics Market worth $3.51 billion by 2030 with 5.2% CAGR |…

Browse in-depth TOC on 'Veterinary Biologics Market'312 - Tables61 - Figures316 - Pages Browse in-depth TOC on 'Veterinary Biologics Market' 312 - Tables 61 - Figures 316 - Pages By product type,monoclonal antibodies are expected to register a high growth rate in the veterinary biologics market, driven by their targeted mechanism of action, high efficacy, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific...
PR Newswire
30/10/2025

Signant Health Appoints Internationally Recognized Cognitive Assessment Expert…

John will work closely with Signant's David Miller, a renowned expert in Alzheimer's and other dementias and co-author of the ADAS-Cog scoring manual, to strengthen the company's cognitive assessment capabilities. His role will focus on driving innovation in clinical outcome assessments for CNS trials, with particular emphasis on Alzheimer's disease, dementia, and complex neurological conditions where cognitive endpoints play a central role in regulatory decision-making. John will work…
PR Newswire
30/10/2025

Hoag selects Philips to enhance and unify patient monitoring, elevating care…

10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport Beach, Calif., USA–Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, andHoag, Orange County, California’s highest-ranked hospital, today announced a landmark 10-year strategic collaboration. The initiative will standardize and modernize patient monitoring...
Nasdaq GlobeNewswire
30/10/2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter 2025Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027The exercises have reduced the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 millionCOPENHAGEN, Denmark, October 30, 2025 -...
Nasdaq GlobeNewswire
30/10/2025

T-knife Therapeutics Announces Four Upcoming Data Presentations on…

-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 -- PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neck SAN FRANCISCO and BERLIN, Oct.30, 2025(GLOBE NEWSWIRE) -- T-knife...
Nasdaq GlobeNewswire
30/10/2025
Altri  Comunicati